Cutaneous Microbiota Evolution in ICU Patients With CVC (ICMc)

Sponsor
Centre Hospitalier de Cayenne (Other)
Overall Status
Recruiting
CT.gov ID
NCT06095076
Collaborator
Tropical Biome and ImmunoPhysiopathology (TBIP) - French Guiana University (Université de Guyane) (Other)
120
1
12
10

Study Details

Study Description

Brief Summary

Intensive Care Unit (ICU) patients are exposed to catheter-related infections with an important morbidity. Catheter colonization is constant but infection is not. Cutaneous dysbiosis could be the missing link. Our study aims to evaluate the evolution of cutaneous microbiota in ICU patients with a central venous catheter in place, through metagenomics. Our main objective is to evaluate the evolution of alpha-diversity, quantified by intra-patient variation of Shannon diversity index (a diversity index used in bacterial metagenomics).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Skin swabbing
  • Other: Data collection

Detailed Description

Central venous catheters (CVCs) are necessary in up to 60% of ICU patients, representing a risk of catheter-related infections with high morbidity and mortality. Catheter colonization originating mostly from the skin is constant, but infection is not. Dysbiosis is known to be associated with pathological states and infection, for example post-antibiotic C. difficile diarrheas, or atopic dermatitis, in which flares are associated with dysbiosis and S. aureus predominance. Cutanous dysbiosis could be the missing link between catheter colonization and infection. Our hypothesis is that under the influence of multiple ICU factors (stress, antibiotic administration, local dysinfection procedures), cutaneous dybiosis appears in ICU patients with a central venous catheter.

All adult ICU patients with an indication for CVC placement will be included over a 6 months period. Skin swabbing will be performed on CVC insertion site before CVC placement (baseline), and then every 3 days (or when dressing is changed) while CVC is in place, then at ICU discharge. Bacterial metagenomics using bacterial DNA extraction, 16S PCR amplification and Nanopore sequencing will allow for description of cutaneous microbiota and diversity evaluation through Shannon index. Evolution of alpha-diversity will be evaluated through time-series data analysis: comparison of Shannon index at various time points with baseline Shanonn index (before CVC placement). Standard microbiologic culture of skin swabbing will be performed. General patient characteristics and informations relative to CVC infection and treatment will be collected.

This study will have no impact on patient management.

Category 3 Non-Interventional Human Person Research (RIPH 3)

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Descriptive Study of the Cutaneous Microbiota of ICU Patients With Central Venous Catheter (ICMc)
Actual Study Start Date :
Jun 2, 2023
Anticipated Primary Completion Date :
Dec 2, 2023
Anticipated Study Completion Date :
Jun 2, 2024

Outcome Measures

Primary Outcome Measures

  1. Evolution of alpha-diversity [Baseline]

    Comparison of Shannon index at various time points with baseline Shannon index (before Central Venous Catheter placement through leaving intensive care service). The higher the Shannon index, the greater the diversity.

  2. Evolution of alpha-diversity [Day 3]

    Comparison of Shannon index at various time points with baseline Shannon index (before Central Venous Catheter placement through leaving intensive care service). The higher the Shannon index, the greater the diversity.

Secondary Outcome Measures

  1. Skin swabs Metagenomics [Baseline]

    Metagenomics: Alpha and beta-diversity of skin swabs

  2. Skin colonization [Baseline]

    Skin colonization: positive standard culture of skin swabs

  3. Catheter-related colonization [Baseline]

    Catheter-related colonization: standard central line culture positivity

  4. Central Venous Catheter's Metagenomics [Baseline]

    Metagenomics: alpha and beta-diversity of Central Venous Catheter at removal

  5. Catheter related Infection [Baseline]

    Clinical signs and blood culture and/or positive catheter culture

  6. Skin swabs Metagenomics [Day 3]

    Comparison of Shannon index at various time points with baseline Shannon index (before Central Venous Catheter placement through leaving intensive care service). The higher the Shannon index, the greater the diversity.

  7. Skin colonization [Day 3]

    Skin colonization: positive standard culture of skin swabs

  8. Catheter-related colonization [Day 3]

    Catheter-related colonization: standard central line culture positivity

  9. Central Venous Catheter's Metagenomics [Day 3]

    Metagenomics: alpha and beta-diversity of Central Venous Catheter at removal

  10. Catheter related Infection [Day 3]

    Clinical signs and blood culture and/or positive catheter culture

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Adult hospitalized in ICU at the Cayenne Hospital Center in whom the installation of a CVC is indicated
Exclusion Criteria:
  • Patient under 18 years of age

  • Patient or trusted person or family or relative objecting to participation in the study (refusal)

  • Patient under judicial safeguard or under any other protective regime (guardianship or curatorship)

  • Patient with cutaneous lesions (infection, burn) near the cutaneous insertion site of the CVC

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier de Cayenne Cayenne Guyane Française French Guiana 97306

Sponsors and Collaborators

  • Centre Hospitalier de Cayenne
  • Tropical Biome and ImmunoPhysiopathology (TBIP) - French Guiana University (Université de Guyane)

Investigators

  • Principal Investigator: Ariane ROUJANSKY, Centre Hospitalier de Cayenne

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Centre Hospitalier de Cayenne
ClinicalTrials.gov Identifier:
NCT06095076
Other Study ID Numbers:
  • 2023_006
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier de Cayenne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023